Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 4
2017 43
2018 242
2019 413
2020 593
2021 817
2022 1005
2023 934
2024 563

Search Results

4,005 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY).
Yabe D, Shiki K, Homma G, Meinicke T, Ogura Y, Seino Y; EMPA-ELDERLY Investigators. Yabe D, et al. Diabetes Obes Metab. 2023 Dec;25(12):3538-3548. doi: 10.1111/dom.15249. Epub 2023 Aug 25. Diabetes Obes Metab. 2023. PMID: 37622398 Clinical Trial.
Sodium-Glucose Cotransporter 2 Inhibitors.
Erol Ç. Erol Ç. Anatol J Cardiol. 2024 May;28(5):216. doi: 10.14744/AnatolJCardiol.2024.5. Anatol J Cardiol. 2024. PMID: 38686395 Free PMC article. No abstract available.
SGLT2 Inhibitors: The Sweet Success for Kidneys.
Dharia A, Khan A, Sridhar VS, Cherney DZI. Dharia A, et al. Annu Rev Med. 2023 Jan 27;74:369-384. doi: 10.1146/annurev-med-042921-102135. Annu Rev Med. 2023. PMID: 36706745 Free article. Review.
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, Mathieu C, Pedersen SD, Davies M. Frias JP, et al. Lancet. 2023 Aug 26;402(10403):720-730. doi: 10.1016/S0140-6736(23)01163-7. Epub 2023 Jun 23. Lancet. 2023. PMID: 37364590 Clinical Trial.
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Patel SM, Kang YM, Im K, Neuen BL, Anker SD, Bhatt DL, Butler J, Cherney DZI, Claggett BL, Fletcher RA, Herrington WG, Inzucchi SE, Jardine MJ, Mahaffey KW, McGuire DK, McMurray JJV, Neal B, Packer M, Perkovic V, Solomon SD, Staplin N, Vaduganathan M, Wanner C, Wheeler DC, Zannad F, Zhao Y, Heerspink HJL, Sabatine MS, Wiviott SD. Patel SM, et al. Circulation. 2024 Jun 4;149(23):1789-1801. doi: 10.1161/CIRCULATIONAHA.124.069568. Epub 2024 Apr 7. Circulation. 2024. PMID: 38583093 Free PMC article.
4,005 results